Welcome to our dedicated page for AKUS news (Ticker: AKUS), a resource for investors and traders seeking the latest updates and insights on AKUS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AKUS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AKUS's position in the market.
Akouos (Nasdaq: AKUS) reported its financial results for Q4 and the full year ended December 31, 2021, showing a net loss of $24.9 million, or $0.72 per share, for Q4, and an $86.7 million loss, or $2.52 per share, for the full year. The company ended 2021 with a cash position of $232.5 million, down from $308 million in 2020. Akouos is on track for IND submissions for AK-OTOF and AK-antiVEGF in 2022 and has expanded its leadership team with the appointment of Aaron Tward as Chief Scientific Officer.
Akouos (NASDAQ: AKUS) announced participation in two virtual investor conferences.
CEO Manny Simons will present on March 30 at the H.C. Wainwright Gene Therapy and Gene Editing Conference, with a pre-recorded presentation available at 7:00 a.m. EST and a panel discussion at 1:00 p.m. EST. On March 31, he will attend the Guggenheim Genomic Medicines & Rare Disease Day.
Webcasts for these events will be accessible on the Akouos website, with archived replays available for 30 days.
Akouos, Inc. (NASDAQ: AKUS) has appointed Aaron Tward, M.D., Ph.D., as the new chief scientific officer. Dr. Tward, who has served on the company’s scientific advisory board since 2018, brings extensive expertise in genetics and gene therapy. His role will focus on advancing Akouos' research in precision genetic medicine aimed at treating inner ear conditions. Dr. Tward’s experience includes work at UCSF and the Broad Institute, and he has authored over 30 peer-reviewed publications. This leadership change aims to strengthen the company's pipeline of gene therapies for hearing loss.
Akouos (NASDAQ: AKUS), a precision genetic medicine company, announced that its CEO, Manny Simons, Ph.D., will participate in a panel discussion on Auditory and Ophthalmology at the Cowen 42nd Annual Health Care Conference on March 7 at 2:10 p.m. EST. The event will be streamed live on the company's website, with replays available for 30 days. Akouos focuses on gene therapies aimed at restoring hearing for those with disabling hearing loss, utilizing a proprietary adeno-associated viral (AAV) vector library.
Akouos, Inc. presented nonclinical data supporting the future development of gene therapies for inner ear conditions at the ARO 45th Annual Meeting. Key findings include robust local expression and tolerability of AK-antiVEGF for treating vestibular schwannomas, enhancing safety over systemic therapies. A tailored gene delivery method using AAVAnc80 showed selective expression in supporting cells while sparing hair cells. The company aims for IND submissions for AK-OTOF and AK-antiVEGF in 2022, expanding its capabilities in gene therapies for hearing loss.
Akouos, a precision genetic medicine company focused on gene therapies for disabling hearing loss, will participate in two virtual investor conferences in February. The Cowen 2nd Annual Genetic Medicines Summit features a panel discussion on February 3, while the 11th Annual SVB Leerink Global Healthcare Conference includes a presentation by CEO Manny Simons on February 16. Both events aim to highlight advancements in genetic therapies. A live webcast will be available on Akouos's website, with an archived replay accessible for 30 days afterwards.
Akouos, a Boston-based precision genetic medicine company, has announced it will present new nonclinical data at the ARO 45th Annual Mid-Winter Meeting in San Jose, California, from February 5 to 9, 2022. The presentations will focus on AK-antiVEGF, a gene therapy aimed at treating vestibular schwannoma, showcasing Akouos' capabilities in addressing various inner ear conditions. Key presentations on February 6 include topics on drug delivery and gene silencing methods, presented by leading researchers in the field.
Akouos, a precision genetic medicine company focused on gene therapies for hearing loss, announced that CEO Manny Simons participated in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Healthcare Conference. This event will occur from November 29 to December 2, 2021. The chat will be available on Akouos's website starting November 22, 2021, for 14 days. Akouos aims to develop therapies to restore and improve hearing for individuals suffering from disabling hearing loss, utilizing proprietary AAV vectors and innovative delivery methods.
Akouos, Inc. (Nasdaq: AKUS) reported progress in its gene therapy pipeline, aiming for IND submissions for AK-OTOF and AK-antiVEGF in 2022. The company appointed Stacy Price as chief technical officer to enhance operational capabilities. Financial results for Q3 2021 include a cash position of $249.7 million, R&D expenses of $17.4 million, and a net loss of $22.9 million, compared to a net loss of $13.1 million in Q3 2020. The company expects its cash reserves to sustain operations for at least two years.
Akouos, Inc. (NASDAQ: AKUS) announced the appointment of Stacy Price as Chief Technical Officer, bringing over 25 years of experience in biotechnology and gene therapy. Price will oversee vector development and manufacturing as well as device engineering. Her prior roles include Senior Vice President at Ziopharm Oncology and Head of Pharmaceutical Development at Shire. Akouos is progressing its AK-OTOF and AK-antiVEGF programs towards IND submissions in the coming year, aiming to enhance its precision genetic medicine platform dedicated to treating disabling hearing loss.
FAQ
What is the market cap of AKUS (AKUS)?
